Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT05480449 is registered in ClinicalTrials.gov with Stephan Grupp MD PhD as lead sponsor.

NCT NCT05480449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)
Lead sponsor
Stephan Grupp MD PhD
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 20, 2022
Completion date
September 20, 2029
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell acute lymphoblastic leukemia (b-all), b lineage lymphoblastic lymphoma